Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis
Helen Jarvis, Hannah O’Keefe, Dawn Craig, et al.
BMJ Open (2022) Vol. 12, Iss. 1, pp. e049767-e049767
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 314
Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease
Fredrik Åberg, Christopher D. Byrne, Carlos J. Pirola, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 1, pp. 191-206
Open Access | Times Cited: 151
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 764-783
Closed Access | Times Cited: 96
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2023) Vol. 17, Iss. 4, pp. 773-791
Open Access | Times Cited: 91
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 59
The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus
Xufen Zeng, Krista A Varady, Xiangdong Wang, et al.
Metabolism (2024) Vol. 161, pp. 156028-156028
Closed Access | Times Cited: 23
Alcohol-associated liver disease—Global epidemiology
Fredrik Åberg, Z. Gordon Jiang, Helena Cortez‐Pinto, et al.
Hepatology (2024) Vol. 80, Iss. 6, pp. 1307-1322
Closed Access | Times Cited: 16
NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy
Matthias Pinter, David J. Pinato, Pierluigi Ramadori, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 3, pp. 513-520
Open Access | Times Cited: 59
Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
Nobuharu Tamaki, Takefumi Kimura, Shun‐ichi Wakabayashi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 1, pp. 61-69
Closed Access | Times Cited: 15
New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice
Clémence M. Canivet, Jérôme Boursier, Rohit Loomba
Seminars in Liver Disease (2024) Vol. 44, Iss. 01, pp. 035-042
Closed Access | Times Cited: 9
MetALD: Does it require a different therapeutic option?
George Marek, Harmeet Malhi
Hepatology (2024) Vol. 80, Iss. 6, pp. 1424-1440
Closed Access | Times Cited: 8
Prophylactic effects of nutrition, dietary strategies, exercise, lifestyle and environment on nonalcoholic fatty liver disease
Xiangyong Hao, Hao Song, Xin Su, et al.
Annals of Medicine (2025) Vol. 57, Iss. 1
Open Access | Times Cited: 1
Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
Daniel Clayton‐Chubb, William Kemp, Ammar Majeed, et al.
Nutrients (2023) Vol. 15, Iss. 3, pp. 687-687
Open Access | Times Cited: 22
MASLD treatment—a shift in the paradigm is imminent
Mariana Verdelho Machado
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 18
Meta‐analysis: The impact of light‐to‐moderate alcohol consumption on progressive non‐alcoholic fatty liver disease
Louise Magherman, Robbe Van Parys, N. Pauwels, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 8, pp. 820-836
Open Access | Times Cited: 17
Validation of fatty liver index as a predictor of hepatic steatosis in Asian populations: Impact of alcohol consumption and sex
Takako Nomura, Masafumi Ono, Kiyoyuki Kobayashi, et al.
Hepatology Research (2023) Vol. 53, Iss. 10, pp. 968-977
Closed Access | Times Cited: 11
Alcohol and heart failure: A complex relationship!
Julian Hoevelmann, Mark C. Petrie, Bernhard Haring
European Journal of Heart Failure (2025)
Open Access
Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment
Christopher D. Byrne, Angelo Armandi, Vanessa Pellegrinelli, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access
Liver and Atherosclerotic Risk of Alcohol Consumption in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
Shaowen Wang, C. H. Wang, Yu‐Ming Cheng, et al.
Atherosclerosis (2025) Vol. 403, pp. 119161-119161
Closed Access
Metabolic dysfunction associated steatotic liver disease in lean patients. Diagnostic and treatment challenges
E. E. Zabotina, Yu. A. Khabarova, N. Yu. Stukova
Experimental and Clinical Gastroenterology (2025), Iss. 9, pp. 96-109
Closed Access
Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease
В. Т. Ивашкин, О. М. Драпкина, M. V. Maevskaya, et al.
Russian Journal of Gastroenterology Hepatology Coloproctology (2025) Vol. 35, Iss. 1, pp. 94-152
Open Access
MetALD: New Perspectives on an Old Overlooked Disease
Gustavo Ayares, Luis Antonio Díaz, Francisco Idalsoaga, et al.
Liver International (2025) Vol. 45, Iss. 5
Open Access
Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes
Juan Vaz, Patrik Nasr, Anders Helander, et al.
Journal of Hepatology (2025)
Open Access
Subgroups of Steatotic Liver Disease have distinct clinical phenotypes
Katrīna Pekarska, Laura G. Burke, Ian Rowe, et al.
Journal of Clinical and Experimental Hepatology (2025), pp. 102587-102587
Open Access
The importance of patient engagement in the multimodal treatment of MASLD
Joost Boeckmans, Hannes Hagström, Donna R. Cryer, et al.
Communications Medicine (2025) Vol. 5, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top